Revvity Inc.
RVTY Healthcare Diagnostics & Research
Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024. In the quarter to June 2026, revenue grew 1.31%, EPS grew 2.17%, free cash flow grew 59.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow RVTY
Revvity Inc. (RVTY) Revenue
Revvity Inc.'s revenue for fiscal 2025 was $2.9B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $2.9B. Over the past ten years it has ranged from $2.1B (fiscal 2015) to $3.8B (fiscal 2021); the current reading is higher than 73% of that period. Revvity Inc. ranks 13th of 50 Diagnostics & Research companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.9B | 3.67% |
| FY2024 | $2.8B | 0.16% |
| FY2023 | $2.8B | (16.95%) |
| FY2022 | $3.3B | (13.48%) |
| FY2021 | $3.8B | 43.73% |
| FY2020 | $2.7B | (7.64%) |
| FY2019 | $2.9B | 3.80% |
| FY2018 | $2.8B | 23.08% |
| FY2017 | $2.3B | 6.69% |
| FY2016 | $2.1B | 0.51% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $729.7M | 2.61% |
| Mar 2026 | $711.1M | (7.89%) |
| Dec 2025 | $772.1M | 10.46% |
| Sep 2025 | $698.9M | (2.96%) |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| LH Labcorp Holdings Inc. compare | $14.3B |
| DGX Quest Diagnostics Incorporated compare | $11.6B |
| ICLR ICON PLC compare | $8.3B |
| CRL Charles River Laboratories International, Inc. compare | $4.0B |
| RVTY Revvity Inc. | $2.9B |
| MEDP Medpace Holdings, Inc. compare | $2.8B |
| QGEN QIAGEN N.V. compare | $2.1B |
| GH Guardant Health, Inc. compare | $1.2B |
| TWST Twist Bioscience Corporation compare | $431.8M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on RVTY
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement